We've merged with Palleos Healthcare to form a wide-reaching European CRO.
Find out more
Yesterday, news came that Cereno Scientific, with the assistance of clinical research organization OCT Group, had received approval for the planned Phase II study with CS1 in Bulgaria – the second and last country to host the phase II study with CS1. BioStock contacted CEO Sten R. Sörensen, currently at an “Anti-Fibrotic Drug Development” conference in Boston, for a comment.
In late September, Cereno Scientific’s got a CTA approval to conduct a Phase II clinical trial with CS1 to evaluate the candidate’s ability to prevent thrombosis.
Read the full article at BioStock official website. [1]
OCT Clinical is now operating under Palleos Healthcare brand name.
“The merger will undoubtedly create significant synergies, not just doubling but squaring the expertise of both companies”, Philip Räth, Ph.D., managing director at Palleos, said in the release.
“OCT Clinical is proud to join forces with palleos healthcare, as it has an excellent reputation in the industry it serves. Now we can offer tailored solutions to our clients to meet their diverse clinical research needs and accelerate the time of bringing their products to market”, Dmitry Sharov, CEO at OCT Clinical.
